Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

Author(s):

Ticiana A. Leal, MD,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

Now Viewing

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Briefly explore the current landscape of first-line treatment for limited-stage small cell lung cancer:
1. What clinical factors influence or impact the initial diagnostic workup and management of patients with LS-SCLC?
2. To what degree is a multidisciplinary team approach adopted when developing a treatment plan for patients with SCLC?
3. With respect to limited-stage disease, which patients are most likely to benefit from surgery and does lobectomy remain the preferred procedure for stageI-IIA (T1-2,N0,M0) disease?
4. To what degree does pathologic mediastinal lymph node stage influence your treatment path?
Under what circumstances would surgery versus RT be a preferred approach for a patient with stage I-IIA SCLC?